{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-24-000367","form_type":"8-K","ticker":null,"cik":"0001476963","company_name":"Scorpius Holdings, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.284919+00:00","generated_at":"2026-06-04T22:07:53.147565+00:00","sec_items":["1.01","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Scorpius extends rights plan to March 2025; closes 10M-share public offering for $1.5M","bullets":["Amendment No. 7 extends stockholder rights plan expiration to March 11, 2025, or earlier redemption/exchange.","Closed public offering of 10,000,000 common shares at $0.15 per share for $1.5M gross proceeds.","Net proceeds will be used for working capital and general corporate purposes.","ThinkEquity acted as sole book-running manager for the offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-24-000367","json":"https://secwatch.observer/filing/0001079973-24-000367.json","markdown":"https://secwatch.observer/filing/0001079973-24-000367.md","text":"https://secwatch.observer/filing/0001079973-24-000367.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1476963/000107997324000367/0001079973-24-000367-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1476963/000107997324000367/scpx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:07:53.147565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"74af719fa08943331432a7e8fdaa989f4cbf5670","claim":"Scorpius Holdings, Inc. amended Amendment No. 7 with Continental Stock Transfer & Trust Company (effective 2024-03-11).","evidence_excerpt":"On March 11, 2024, Scorpius Holdings, Inc. (formerly known as NightHawk Biosciences, Inc.) (the “Company”) entered into Amendment No. 7 (“Amendment No. 7”) dated March 11, 2024 to the Rights Agreement dated March 11, 2018 (the “Original Rights Agreement”), as amended by Amendment No. 1 thereto (“Amendment No. 1”) dated March 8, 2019, Amendment No. 2 thereto (“Amendment No. 2”) dated March 10, 2020, Amendment No. 3 thereto (“Amendment No. 3”) dated March 8, 2021, Amendment No. 4 thereto (“Amendment No. 4”) dated March 11, 2022, Amendment No. 5 thereto (“Amendment No. 5”) dated March 11, 2023, and Amendment No. 6 thereto (“Amendment No. 6”) dated December 11, 2023 (collectively, the “Rights Agreement”) by and between the Company and Continental Stock Transfer & Trust Company, as rights agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1476963/000107997324000367/0001079973-24-000367-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Continental Stock Transfer & Trust Company"},{"label":"Effective","value":"2024-03-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}